New strategies with anti-IgE in allergic diseases
详细信息 查看全文
- 作者：Stephen T Holgate
- 关键词：Omalizumab ; Anti ; IgE monoclonal antibody ; Asthma ; Comorbidity ; Allergy
- 刊名：World Allergy Organization Journal
- 出版年：2014
- 出版时间：December 2014
- 年：2014
- 卷：7
- 期：1
- 全文大小：2,326 KB
- 参考文献：1. Frankland, AW (2004) Carl Prausnitz: a personal memoir. J Allergy Clin Immunol 114: pp. 700-704 class="external" href="http://dx.doi.org/10.1016/j.jaci.2004.06.040" target="_blank" title="It opens in new window">CrossRef
2. Ishizaka, K, Ishizaka, T, Hornbrook, M (1966) Physicochemical properties of reaginic antibody. V. Correlation of reaginic activity and E-globulin antibody. J Immunol 97: pp. 840-853
3. Broide, DH (2001) Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 108: pp. S65-S71 class="external" href="http://dx.doi.org/10.1067/mai.2001.116436" target="_blank" title="It opens in new window">CrossRef
4. Sharquie, IK, Al-Ghouleh, A, Fitton, P, Clark, MR, Armour, KL, Sewell, HF, Shakib, F, Ghaemmaghami, AM (2013) An investigation into IgE-facilitated allergen recognition and presentation by human dendritic cells. BMC Immunol 14: pp. 54 class="external" href="http://dx.doi.org/10.1186/1471-2172-14-54" target="_blank" title="It opens in new window">CrossRef
5. Baird, B, Shopes, RJ, Oi, VT, Erickson, J, Kane, P, Holowka, D (1989) Interaction of IgE with its high-affinity receptor. Structural basis and requirements for effective cross-linking. Int Arch Allergy Appl Immunol 88: pp. 23-28 class="external" href="http://dx.doi.org/10.1159/000234742" target="_blank" title="It opens in new window">CrossRef
6. Heusser, C, Jardieu, P (1997) Therapeutic potential of anti-IgE antibodies. Curr Opin Immunol 9: pp. 805-813 class="external" href="http://dx.doi.org/10.1016/S0952-7915(97)80182-3" target="_blank" title="It opens in new window">CrossRef
7. Corne, J, Djukanovic, R, Thomas, L, Warner, J, Botta, L, Grandordy, B, Gygax, D, Heusser, C, Patalano, F, Richardson, W, Kilchherr, E, Staehelin, T, Davis, F, Gordon, W, Sun, L, Liou, R, Wang, G, Chang, TW, Holgate, S (1997) The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest 99: pp. 879-887 class="external" href="http://dx.doi.org/10.1172/JCI119252" target="_blank" title="It opens in new window">CrossRef
8. Easthope, S, Jarvis, B (2001) Omalizumab. Drugs 61: pp. 253-260 class="external" href="http://dx.doi.org/10.2165/00003495-200161020-00008" target="_blank" title="It opens in new window">CrossRef
9. Normansell, R, Walker, S, Milan, SJ, Walters, EH, Nair, P (2014) Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 1: pp. CD003559
10. Campbell, JD, McQueen, RB, Briggs, A (2014) The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. Ann Am Thorac Soc 11: pp. S105-S111 class="external" href="http://dx.doi.org/10.1513/AnnalsATS.201309-295RM" target="_blank" title="It opens in new window">CrossRef
11. Long, A, Rahmaoui, A, Rothman, KJ, Guinan, E, Eisner, M, Bradley, MS, Iribarren, C, Chen, H, Carrigan, G, Rosén, K, Szefler, S (2014) Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol pii: S0091-6749: pp. 00204-8
12. Kim, HL, Leigh, R, Becker, A (2010) Omalizumab: Practical considerations regarding the risk of anaphylaxis. Allergy Asthma Clin Immunol 6: pp. 32 class="external" href="http://dx.doi.org/10.1186/1710-1492-6-32" target="_blank" title="It opens in new window">CrossRef
13. Bousquet, J, Rabe, K, Humbert, M, Chung, KF, Berger, W, Fox, H, Ayre, G, Chen, H, Thomas, K, Blogg, M, Holgate, S (2007) Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 101: pp. 1483-1492 class="external" href="http://dx.doi.org/10.1016/j.rmed.2007.01.011" target="_blank" title="It opens in new window">CrossRef
14. MacGlashan, DJ (2004) Loss of receptors and IgE in vivo during treatment with anti-IgE antibody. Allergy Clin Immunol 114: pp. 1472-1474 class="external" href="http://dx.doi.org/10.1016/j.jaci.2004.07.064" target="_blank" title="It opens in new window">CrossRef
15. Schroeder, JT, Bieneman, AP, Chichester, KL, Hamilton, RG, Xiao, H, Saini, SS, Liu, MC (2010) Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization. J Allergy Clin Immunol 125: pp. 896-901 class="external" href="http://dx.doi.org/10.1016/j.jaci.2009.10.021" target="_blank" title="It opens in new window">CrossRef
16. van Rensen, EL, Evertse, CE, van Schadewijk, WA, van Wijngaarden, S, Ayre, G, Mauad, T, Hiemstra, PS, Sterk, PJ, Rabe, KF (2009) Allergy. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy 64: pp. 72-80 class="external" href="http://dx.doi.org/10.1111/j.1398-9995.2008.01881.x" target="_blank" title="It opens in new window">CrossRef
17. Prieto, L, Gutiérrez, V, Colás, C, - 刊物主题：Allergology;
- 出版者：BioMed Central
- ISSN：1939-4551
文摘
IgE has long been known as a therapeutic target for allergic disease, but the difficulty has been in selecting agents that don't trigger cross linkage of IgE when bound to its high affinity receptor (FceR1) on mast cells and basophils. By “designing-a monoclonal antibody (mAb) which targets that part of IgE that binds to that binds to the a-chain of FceR1, the allergic cascade can be effectively interrupted and diseases such as asthma greatly improved, providing a substantial part of their phenotype engages IgE. Clinical trials and real life studies confirm this. Beyond asthma, a whole range of other diseases dependent upon IgE initiation and triggering are being identified. These diseases are now being explored as being amenable to anti-IgE therapy some of which are comorbidities of asthma and others not. The advent of an even more potent anti-IgE mAb - QGE031 -is creating further opportunities for anti-IgE therapy to improve the lives of so many people with IgE-related diseases.